The radiodermatitis market size is estimated to be USD 452.47 million in 2022 and is expected to witness a CAGR of 4.31% during the forecast period 2023-2033. Surge in incidence of radiodermatitis as a result of radiotherapy treatment, rise in public and private healthcare organization, and increase in clinical studies being undertaken to expand the product pipeline are projected to drive the market growth in near future. Furthermore, rising rates of cancer globally and increasing number of governmental and private healthcare organisations actively seeking to promote awareness about the management and treatment of radiodermatitis However, high price and adverse effects of treatment are predicted to limit market growth are expected to restrain the market growth.

Rising rates of cancer globally is expected to propel the market growth during the projected period. According to statistics published by the World Health Organization (WHO), the United Nations (UN) specialised agency in charge of public health, cancer would account for over 10 million deaths worldwide in 2020. Additionally, in 2020, breast cancer and non-melanoma skin cancer accounted for 1.20 million cases each. As a result, it is anticipated that the use of radiodermatitis treatments will significantly grow throughout the world during the projected period, thus supporting the radiodermatitis market.

Increasing number of governmental and private healthcare organisations actively seeking to promote awareness about the management and treatment of radiodermatitis is predicted to spur the market growth during the forecast period. These groups also provide information on ways to treat the disease effectively, which is anticipated to raise the potential for growth throughout the course of the forecast period. For instance, the BC Cancer Agency of the Provincial Health Services Authority has published data on radiodermatitis risk factors and guidelines for treating the condition’s symptoms. This is expected to increase understanding of assessment and treatment techniques and general skincare guidance, enhancing potential growth.

Segmentation

 By Product

The market is categorized into dressings, topical, and oral. In 2022, the topical segment accounted for the highest revenue share due to the benefits of topical products. These benefits, which include ease of use, accessibility, and improved cost, are among the main factors influencing the popularity of these products throughout the previous years. Topical medications also reduce the risk of microbial spread and protect the skin from abrasives substances. Topical antibiotics, hydrophilic creams, and corticosteroids are a few of the important products that fall under this group. Corticosteroids made up the majority of topical medications due to their position as the gold standard in the treatment of inflammatory skin conditions, which led to their adoption for the treatment of radiodermatitis. Dressings are predicted to increase at a moderate rate over the upcoming years due to the large variety of products available on the market. These products come in a variety of forms, such as foam-based, silicone-coated, hydrogel & hydrocolloid, silver-leaf dressings, and more. Dressings have been found to be helpful in treating various grades of radiation burns, which is expected to accelerate their acceptance in the coming years.

By Distribution Channel

The market is segmented into online pharmacies, hospital pharmacies, and retail pharmacies. In the global market, the retail pharmacies segment accounted for the largest revenue share in 2022 owing to high accessibility and cost of retail establishments. Patients are encouraged to depend on retail pharmacies by drug cost reimbursement, which boosts the market’s potential for growth due to affordability. Online pharmacies are anticipated to have exponential growth rates throughout the course of the forecast period due to a number of advantages, including greater convenience for clients who don’t want to purchase their prescriptions from retail or hospital pharmacies. In addition, there is a mismatch between supply and demand of essential drugs as a result of the rise in chronic diseases. These reasons will result in a rise in demand for online pharmacies over the course of the expected time period. Online pharmacies make it simple for customers to place orders and keep track of them. Additionally, connected supply chain management (SCM) eliminates some of the market middlemen, which lowers the overall drug price and increases consumers’ propensity to buy medications online.

Regional Markets

In 2022, Asia Pacific region accounted for the highest revenue in the radiodermatitis market and is expected to maintain its dominance during the forecast period. This is attributed to rising number of cancer patients in this region. The higher market share that this region has achieved is also a result of extensive collaborations between major companies to boost their capacity for product variety expansion. Additionally, well-known pharmaceutical companies in this region are actively involved in the promotion of end-user adoption and the sale of their products. Positive government initiatives that encourage research activity and an increase in outsourcing by industrialized economies are key growth factors for this region. The second-highest market share was held by North America. The main factors driving this market are the significant R&D expenditures made by global players and their dedication to securing a competitive position in the industry. Furthermore, there are enormous expansion opportunities throughout the region due to the high disposable income and the availability of advanced healthcare infrastructure.

Competitor Insights

Some of the key players operating in the radiodermatitis market are 3M, BMG Pharma S.R.L.,
Stratpharma AG, ConvaTec Inc., Acelity, Smith & Nephew, Molnlycke Health Care AB, Alliqua BioMedical, Derma Sciences Inc., and The Jackson Laboratory.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, Triad Life Sciences Inc.’s acquisition by Convatec Group Plc was announced in March 2022. The acquisition improves the company’s better wound management and patient outcomes.Additionally, CIVCO Radiotherapy and Stratpharma AG collaborated together in April 2019 to strengthen their focus on radiation therapy patients’ wound care. The expert in providing top-notch, patient-centred radioactive solutions is CIVCO Radiotherapy.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including product and distribution channel from 2022 to 2033.

Report Scope:

Segmentation: Radiodermatitis Market Report 2022 – 2033

Product (Revenue, USD Million), 2022 – 2033

• Dressings
  • Silicone Coated Dressings
  • No Sting Barrier Film
  • Hydrogel & Hydrocolloid dressings
  • Honey-Impregnated Gauze
  • Others
• Topical
  • Antibiotics
  • Corticosteroids
  • Hydrophilic Creams
  • Others
• Oral

Distribution Channel (Revenue, USD Million), 2022 – 2033

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA